The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Site details revisedv7
  2. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2027
    • Site details revised
    v6
  3. Site details revisedv5
  4. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Dec 31, 2023 to Dec 31, 2025
    • Start date changed from estimate of Jun 1, 2023 to Nov 1, 2023
    • Study sites: 0 to 1
    • Study completion date: Jun 30, 2024 to Dec 31, 2025
  5. Start date: Nov 1, 2022 to Jun 1, 2023v3
  6. Start date: Jul 1, 2022 to Nov 1, 2022v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Prof Urs Zingg
5 trials monitored
See all monitored trials
Obesity
3,898 trials monitored
See 160 trials at risk
The objective of this study is to investigate the effect of Esomeprazol administered in tablets (Esomeprazol MUT Sandoz® 40mg) or in solution (Esomeprazol MUT Sandoz® 40mg in 10ml tap water) on acid production in the gastric pouch by measuring the intragastric pH and the serum concentration of esomeprazole.
Trial Details
NCT Number NCT05320796
Lead Sponsor Prof Urs Zingg
Conditions
(from sponsor)		 Obesity, Gastric Reflux, Ulcer, Gastric
Related terms Gastroesophageal Reflux, Obesity, Stomach Ulcer
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov